HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYN

John Schieszer


A Call for Better Screening for Hereditary Renal Cell Carcinoma

July 11, 2018

More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.

Durable Responses in R/R DLBCL With CAR-T Product Lisocabtagene Maraleucel

June 03, 2018

In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.

Cellular Therapies for Multiple Myeloma: A Paradigm Shift

June 01, 2018

Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn’s Adam Cohen at ASCO 2018.

“Off-The-Shelf” Third Party T Cells for CAR-T Therapy Under Investigation

March 15, 2018

Using CRISPR/Cas9 gene editing to remove CD7 from healthy T cells, researchers have found a way to use third party T cells for CAR-T therapy in T-cell hematologic malignancies.

DNA-Demethylating Agents Combined with Histone Deacetylase Inhibitors May Help Combat NSCLC

December 21, 2017

The combination therapy increased the attraction of immune cells to fight non-small cell lung cancer and also boosted the response to immune checkpoint inhibitors.

MMG49 Identified as a New Target in Multiple Myeloma

December 13, 2017

MMG49 has been identified as a monoclonal antibody that can be targeted using CAR T-cell therapy for patients with multiple myeloma.

Combination Therapy Proposed for Multiple Myeloma and Mantle Cell Lymphoma

December 12, 2017

A proof-of-concept study has demonstrated that resistance to treatment in multiple myeloma and mantle cell lymphoma could be linked to a protein called Nrf1, which appears to respond to proteasome insufficiency or pharmacological inhibition.